Clinical trials: Progression of Atherosclerotic Plaque
Plaque, Atherosclerotic, Programmed Cell Death Protein 1 Inhibitor
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
- Trial name
- NCT04922541
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atherosclerotic Disease, Plaque, Atherosclerotic
Natural History of Carotid Plaque as Determined by 3D Ultrasound
This proposed follow-up study aims to recruit participants from the original BioImage cohort for a one-time follow-up examination.
- Conditions
- Atherosclerotic Disease, Plaque, Atherosclerotic, Heart Diseases, Stroke
- Trial name
- BioImage2 (NCT03314818)
- Testing
- Ultrasound 3D Imaging
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Pieter Muntendam
Coronary Heart Disease
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors.
- Trial name
- NCT00655473
- Testing
- Dalcetrapib (RO4607381)
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Atrial Fibrillation
Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Vitamin K-antagonists (VKA) such as warfarin are the most widely used blood thinners for irregular heart beats like atrial fibrillation.
- Trial name
- NCT02090075
- Testing
- apixaban, warfarin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Coronary Artery Disease Progression
Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population
Current guidelines recommend moderate-intensity lipid-lowering therapy (goal for LDL-C <2.6 mmol/L or 30%-50% reduction from baseline) for patients with intermediate 10-year ASCVD risk.
- Trial name
- ILLUMINATION (NCT05462262)
- Testing
- Intensive lipid-lowering control, Moderate-intensity lipid-lowering control
- Where
- China
- Volunteers
- 2,900 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Carotid Atherosclerosis
Potential Impact of Neuroimmune and Autophagic Alterations on the Progression and Severity of Human Atherosclerotic Process
The hypothesis of this study is that neural regulations of the atherosclerotic plaque, identified in the murine model of atherosclerosis, could also exist in human pathology.
- Trial name
- NCT03922698
- Testing
- No interventions
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Neuromed IRCCS
Diabetes Mellitus, Type 2, Atherosclerosis of Artery
Molecular Mechanisms and Carotid Atherosclerosis
The role of methylase system and Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the accelerated atherosclerotic progression of diabetic patients is unclear.
- Conditions
- Diabetes Mellitus, Type 2, Atherosclerosis of Artery, Atherosclerotic Plaque
- Trial name
- NCT03962686
- Testing
- statin Oral Tablet plus PCSK9i
- Where
- Italy
- Volunteers
- 76 people
- Sponsor
- University of Campania Luigi Vanvitelli
Atherosclerosis of Arteries of the Extremities, Unspecified
Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Atherosclerotic Plaques in Clinical Use
The purpose of this study is to investigate the antiatherogenic effect of GSPE in clinical use
- Trial name
- GSPE (NCT01707615)
- Testing
- GSPE, lifestyle intervention
- Volunteers
- 287 people
- Sponsor
- Jie Qiu
Coronary Artery Disease
MAIN-IMAGE Registry
All comers registry with patients with chronic coronary syndrome or acute coronary syndrome who underwent intracoronary imaging during cardiac catherization.
- Trial name
- MAIN-IMAGE (NCT06302777)
- Where
- 2 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Goethe University
Coronary Artery Disease, Atherosclerosis
Sequential Coronary CT-angiography and Biomarkers
Currently, cardiac computed tomography angiography (CCTA) is a well-implemented non-invasive diagnostic imaging modality in patients with stable chest pain.
- Trial name
- PARSEC-NET (NCT02394262)
- Testing
- Coronary CT-angiography, Assesment of biomarkers involved in atherothrombosis
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- Maastricht University Medical Center
Coronary Arterial Disease (CAD), Coronary Arteriosclerosis
PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques
This is a combined cohort study with retrospectively and prospectively enrolled coronary artery disease (CAD) patients. All the patients will undergo clinical follow-up for up to 5 years, and repeat coronary CTA will be conducted…
- Trial name
- PRACTICE (NCT06794684)
- Where
- 2 sites in China
- Volunteers
- 50,000 people
- Sponsor
- Ruijin Hospital
Coronary Heart Disease (CHD)
REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease
Intensive lipid-lowering therapy is a cornerstone treatment for coronary heart disease (CHD). However, coronary plaque progression persists in a subset of patients even under intensive lipid-lowering therapy, which may be…
- Trial name
- REALISTIC (NCT06936111)
- Testing
- Assessment of residual cholesterol and inflammatory risk factors
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Shanghai Zhongshan Hospital
Progression of Atherosclerotic Plaque, Coronary Artery Disease
Coronary Chronic Total Occlusion and Oxidative Balance
The presence of chronic blockage of coronary arteries, which we may accept as the terminal point of atherosclerotic coronary artery disease, is closely associated with a poor prognosis.
- Trial name
- NCT04754880
- Testing
- Comparison of oxidative and antioxidative markers between groups
- Where
- Turkey (Türkiye)
- Volunteers
- 1 people
- Sponsor
- Kahramanmaras Sutcu Imam University
Carotid Artery Stenosis
Progression Assessment of Carotid Artery Stenosis by Ultrafast Ultrasound Flow Imaging
Rationale: Approximately 15-20% of strokes originates from an atherosclerotic plaque rupture in the carotid artery. To reduce the risk of stroke, patients should be evaluated for possible carotid endarterectomy (CEA), which is…
- Trial name
- CAS-PRO (NCT05270005)
- Testing
- Ultrasound-based flow imaging, Ultrasound-based strain imaging, Conventional duplex
- Where
- 2 sites in Netherlands
- Volunteers
- 85 people
- Sponsor
- Rijnstate Hospital
Coronary Artery Disease, Diabetes Mellitus, Type 2
CArdioMetabolism and Atherosclerotic PlaqUe progreSsion
Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such…
- Conditions
- Coronary Artery Disease, Diabetes Mellitus, Type 2, Dyslipidemias, Obesity
- Trial name
- CAMPUS (NCT05117424)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Ruijin Hospital
Coronary Artery Disease, Atherosclerosis, Coronary
HIV Infection And Evolvement of Atherosclerotic Plaque
In a prospective multi-center observational study, 200 HIV-infected patients treated with antiretroviral treatment (ART) and who suffered from coronary artery disease (CAD) will be enrolled.
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Hiv, HIV Infections
- Trial name
- HIVE (NCT04810364)
- Testing
- Quantitative coronary angiography, intravascular imaging with percutaneous intervention
- Where
- 2 sites in Russia
- Volunteers
- 1,000 people
- Sponsor
- Central Clinical Hospital of the Russian Academy of Sciences
Coronary Artery Disease
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's…
- Trial name
- V-PLAQUE (NCT05360446)
- Testing
- Inclisiran sodium 300 mg
- Where
- 89 sites in United States, Argentina and 16 more
- Volunteers
- 610 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Heart Disease
Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging(PARADIGM)
To describe the natural history of the coronary atherosclerotic plaque development and progression over time by CCTA with demographic and laboratory data for refinement of risk stratification of patients referred for CCTA.
- Trial name
- PARADIGM (NCT02803411)
- Volunteers
- 2,000 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque
The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.
- Trial name
- Rosuzet-IVUS (NCT03169985)
- Testing
- Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day, Rosuvastatin 20 mg orally once a day
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Samsung Medical Center
Coronary Arteriosclerosis
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy.
- Trial name
- NCT00380939
- Testing
- Atorvastatin, Pravastatin
- Where
- 36 sites in United States
- Volunteers
- 600 people
- Sponsor
- Pfizer